Helus Pharma plans Phase 2 HLP004 anxiety trial for first quarter of 2027

• Helus Pharma expects topline results from its HLP003 APPROACH Phase 3 trial for adjunctive treatment of major depressive disorder in Q4 2026.
• A Phase 2 trial evaluating HLP004 as a standalone treatment for generalized anxiety disorder is expected to begin in Q1 2027.
• The HLP004 study will assess efficacy and safety against placebo in approximately 144 adults.
• HLP003 holds FDA Breakthrough Therapy Designation; Helus Pharma expects to submit a New Drug Application in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-005468), on October 21, 2026, and is solely responsible for the information contained therein.